Yılmaz-Çiftdoğan D, Köse E, Aslan S, Gayyurhan E. Atypical clinical manifestations of hepatitis A among children aged 1-16 years in South-Eastern region of Turkey. Turk J Pediatr 2015; 57: 339-344.Hepatitis A virus (HAV) infection has several atypical manifestations, including fulminant hepatitis, relapsing hepatitis, prolonged cholestasis and extrahepatic manifestations. In this study, we aimed to describe the characteristics and outcomes of the pediatric patients with atypical manifestations of HAV infection. Four hundred twelve children with symptomatic hepatitis A infection admitted to Gaziantep Children's Hospital Department of Pediatric Infectious Disease between August 2011 and January 2013 were analyzed retrospectively. Atypical presentations were present in 53 (12.8%) children of 412 children with HAV infection. Patients with atypical presentations (8.3±3.7 years) were older than patients with typical presentations (5.9±3.1 years) (p=0.001). Children with atypical features of hepatitis A statistically had higher initial and peak values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), international normalized ratio (INR), serum total and direct bilirubin than typical manifested group. We can conclude that older age is the major risk factor for atypical presentation of HAV infections. Higher initial and peak levels of AST, ALT, INR, total and direct bilirubin could predict the atypical manifestation.
___
1. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28: 6653-6657.
2. Hepatitis A vaccines. Wkly Epidemiol Rec 2000; 75: 38-44.
3. Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology 2010; 53: 15-19.
4. Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171: 15-18.
5. Bell BP, Fiore AE. Hepatitis a virus. In: Long SS, Pickering LK, Prober CG, editors. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. China: Churchill Livingstone; 2008: 1157-1162.
6. Ceyhan M, Yıldırım I, Kurt N. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat 2008; l5: 69-72.
7. Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992; 10: 18-20.
8. Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101: 635-637.
9. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001; 14: 38-58.
10. Ciocca M (2000) Clinical course and consequences of hepatitis A infection. Vaccine 2000; 18: 71-74.
11. Çetinkaya B, Tezer H, Özkaya Parlakay A, Revide Sayli T. Evaluation of pediatric patients with hepatitis A. J Infect Dev Ctries 2014; 8: 326-330.